Bachem Holding AG Bachem Holding AG

Bachem Holding AG

BANB

株式のランク #2516
Bachem Holding AG serves pharmaceutical and biotechnology companies globally,... Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
株価
$100.60
時価総額
$7.54B
変化(1日)
-1.49%
変化(1年)
49.53%
国
CH
取引 Bachem Holding AG (BANB)

カテゴリー

Healthcare
Bachem Holding AG(BANB)の収益
Oct 2026 時点の収益 TTM: 0
Bachem Holding AG の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Bachem Holding AG の収益履歴(2002 ~ 2026)
各年末の収益
年 収益 変化
2025 $875.88M 30.72%
2024 $670.05M -2.39%
2023 $686.47M 19.36%
2022 $575.15M 4.20%
2021 $551.97M 23.34%
2020 $447.51M 38.00%
2019 $324.29M 12.93%
2018 $287.17M 6.98%
2017 $268.42M 15.53%
2016 $232.34M 11.33%
2015 $208.69M 12.70%
2014 $185.17M -3.20%
2013 $191.29M 11.30%
2012 $171.87M 10.72%
2011 $155.22M -5.12%
2010 $163.59M -7.04%
2009 $175.99M -3.60%
2008 $182.56M 4.04%
2007 $175.47M 24.55%
2006 $140.88M 20.66%
2005 $116.75M -10.21%
2004 $130.03M 11.21%
2003 $116.92M 7.90%
2002 $108.36M 0.00%
同業他社の収益
企業 収益 収益の差 国
$12.62B -
US
$2.23B -
US
$15.74B -
AU
$6.02B -
NL
- -
CH